Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

The firm decreased its portfolio allocation in MRK by 78.58% over the last quarter. Merck Background Information (This description is provided by the company.) For 130 years, Merck, known as MSD ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

The firm decreased its portfolio allocation in MRK by 78.58% over the last quarter. Merck Background Information (This description is provided by the company.) For 130 years, Merck, known as MSD ...